AI Terminal
Q-Linea
Board/Management Information • Jan 5, 2026
3100_rns_2026-01-05_4cb8d209-7d50-40b2-8df7-4f289c1144c0.pdf
Board/Management Information
Open in ViewerOpens in native device viewer
Q-linea announces changes in US commercial leadership
Q-linea AB (publ) (OMX: QLINEA) today announces that Jim Kathrein will step down as VP US Commercial Operations. Ethan Suttles, who has served as US Director of Strategic Accounts since December 2023, will lead the US sales team and report directly to CEO Stuart Gander as of February 1, 2026.
Jim will support a smooth transition of responsibilities for US activities during Q1 2026. Natalie Brown, Director Global Marketing and Vikas Gupta, Senior Director of Clinical Affairs already hold global roles based in the US and will report directly to Stuart Gander.
CEO, Stuart Gander, comments, "I would like to thank Jim for his successful efforts in establishing a strong US team and building our commercial capabilities in the largest diagnostic market. Our US leadership team with Ethan, Natalie and Vikas representing Sales, Marketing and Clinical Affairs respectively are focused on executing our commercial strategy and converting our growing pipeline of ASTar to clinical use going into 2026."
About Q-linea
Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.
Q-linea's flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.